Results 151 to 160 of about 31,180 (210)
On the Mechanism of Action of Anti-Inflammatory Activity of Hypericin: An In Silico Study Pointing to the Relevance of Janus Kinases Inhibition. [PDF]
Molecules, 2018 Dellafiora L +4 more
europepmc +1 more source
Acta Ophthalmologica, EarlyView.Abstract Purpose To assess the impact of biosimilar ranibizumab and on‐patent faricimab market entry on pricing and utilization trends and describe national variation in off‐label bevacizumab use in Europe. Methods Interrupted time series analysis of quarterly sales data (Q1 2018–Q2 2024) in 11 European countries evaluated ranibizumab utilization and ...
Elif Car +3 more
wiley +1 more source
Driver mutations in Janus kinases in a mouse model of B-cell leukemia induced by deletion of PU.1 and Spi-B. [PDF]
Blood Adv, 2018 Batista CR +8 more
europepmc +1 more source
Alimentary Pharmacology &Therapeutics, EarlyView.In this nationwide study of patients with inflammatory bowel disease, TNF inhibitor use was associated with higher bloodstream infection rates, whereas vedolizumab and ustekinumab was not. Associations differed by pathogen species, and concomitant glucocorticoid use was associated with higher infection rates.
Cæcilie Leding +4 more
wiley +1 more source
British Journal of Haematology, EarlyView.Summary Over the past decade, there has been a substantial increase in the diversity and number of therapeutic options for myeloproliferative neoplasms (MPNs). While many remain within the clinical trial arena, the clinician and patient community have seen more approvals reaching the clinic and a rethink on how best we should be approaching these ...
Trung Q. Ngo +3 more
wiley +1 more source
Regulation of Janus kinases by SOCS proteins. [PDF]
Biochem Soc Trans, 2013 Kershaw NJ +4 more
europepmc +1 more source
Survival outcomes and treatment patterns in myelofibrosis in the JAK inhibitor era
British Journal of Haematology, EarlyView.Summary Data on real‐world survival and treatment patterns in large, unselected myelofibrosis (MF) cohorts remain limited. We analysed 1649 patients with MF diagnosed from 2010 onwards and included in the Spanish Myelofibrosis Registry across 64 centres. Janus kinase (JAK) inhibitors were administered to approximately half of the patients.
Juan‐Carlos Hernández‐Boluda +35 more
wiley +1 more source
Janus kinases: an ideal target for the treatment of autoimmune diseases. [PDF]
J Investig Dermatol Symp Proc, 2013 Gadina M.
europepmc +1 more source
CD47 promotes myeloma cell growth through JAK–STAT3/MYC signalling and is targetable by ruxolitinib
British Journal of Haematology, EarlyView.Summary Cluster of differentiation 47 (CD47), a ‘don't eat me’ immune checkpoint receptor, is frequently overexpressed on multiple myeloma (MM) cells and contributes to immune evasion. While its immune regulatory function is well established, the intrinsic oncogenic role of CD47 remains poorly understood.
Omar Faruq +6 more
wiley +1 more source
Eliminative signaling by Janus kinases: role in the downregulation of associated receptors. [PDF]
J Cell Biochem, 2014 Carbone CJ, Fuchs SY.
europepmc +1 more source